DK1339678T3 - Selektive agonister til EP4-receptor til behandling af osteoporose - Google Patents

Selektive agonister til EP4-receptor til behandling af osteoporose

Info

Publication number
DK1339678T3
DK1339678T3 DK01978757T DK01978757T DK1339678T3 DK 1339678 T3 DK1339678 T3 DK 1339678T3 DK 01978757 T DK01978757 T DK 01978757T DK 01978757 T DK01978757 T DK 01978757T DK 1339678 T3 DK1339678 T3 DK 1339678T3
Authority
DK
Denmark
Prior art keywords
osteoporosis
receptor
treatment
selective agonists
agonists
Prior art date
Application number
DK01978757T
Other languages
English (en)
Inventor
K Keefe Cameron
Bruce A Lefker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1339678T3 publication Critical patent/DK1339678T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
DK01978757T 2000-11-27 2001-11-05 Selektive agonister til EP4-receptor til behandling af osteoporose DK1339678T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en) 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
DK1339678T3 true DK1339678T3 (da) 2008-02-04

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01978757T DK1339678T3 (da) 2000-11-27 2001-11-05 Selektive agonister til EP4-receptor til behandling af osteoporose

Country Status (41)

Country Link
US (3) US6552067B2 (da)
EP (1) EP1339678B1 (da)
JP (2) JP3984164B2 (da)
KR (1) KR20030053063A (da)
CN (1) CN1476429A (da)
AR (1) AR035074A1 (da)
AT (1) ATE374182T1 (da)
AU (1) AU2002210848A1 (da)
BG (1) BG107697A (da)
BR (1) BR0115687A (da)
CA (1) CA2429850C (da)
CY (1) CY1106976T1 (da)
CZ (1) CZ20031257A3 (da)
DE (1) DE60130675T2 (da)
DK (1) DK1339678T3 (da)
EA (1) EA200300379A1 (da)
EC (1) ECSP034623A (da)
EE (1) EE200300246A (da)
ES (1) ES2291361T3 (da)
GT (2) GT200100238A (da)
HN (1) HN2001000266A (da)
HU (1) HUP0400807A2 (da)
IL (1) IL155368A0 (da)
IS (1) IS6775A (da)
MA (1) MA26961A1 (da)
MX (1) MXPA03004623A (da)
NO (1) NO20032360L (da)
NZ (1) NZ525164A (da)
OA (1) OA12533A (da)
PA (1) PA8533901A1 (da)
PE (1) PE20020637A1 (da)
PL (1) PL362030A1 (da)
PT (1) PT1339678E (da)
SI (1) SI1339678T1 (da)
SK (1) SK5562003A3 (da)
SV (1) SV2003000746A (da)
TN (1) TNSN01166A1 (da)
TW (1) TW200424170A (da)
UY (1) UY27038A1 (da)
WO (1) WO2002042268A2 (da)
ZA (1) ZA200302803B (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03004623A (es) * 2000-11-27 2003-09-05 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
EP1409455B1 (en) * 2001-07-16 2006-01-04 F. Hoffmann-La Roche Ag Prostaglandin analogues-as ep4 receptor agonists
ATE366571T1 (de) * 2001-07-16 2007-08-15 Hoffmann La Roche 2 pyrrolidon-derivate als prostanoid-agonisten
ATE500218T1 (de) 2001-07-23 2011-03-15 Ono Pharmaceutical Co Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7402605B2 (en) * 2002-03-05 2008-07-22 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
MXPA04009036A (es) * 2002-03-18 2005-01-25 Pfizer Prod Inc Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular.
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
CA2487977A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
ATE487514T1 (de) * 2002-06-06 2010-11-15 Merck Frosst Canada Ltd 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
EP1556347A4 (en) * 2002-06-10 2006-08-09 Applied Research Systems GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
EP1563846B1 (en) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (en) 2002-11-08 2007-07-25 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
EP1585729A1 (en) * 2003-01-10 2005-10-19 F.Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
JP4582456B2 (ja) * 2003-01-21 2010-11-17 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体およびその医薬用途
JP4662926B2 (ja) 2003-03-03 2011-03-30 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγ−ラクタム誘導体
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
WO2005012232A2 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
WO2005020917A2 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN102558231B (zh) 2003-09-04 2015-05-27 默沙东公司 用于治疗高眼压的眼用组合物
WO2005025568A1 (en) 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
BRPI0417621A (pt) * 2003-12-17 2007-04-10 Pfizer Prod Inc terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2006020003A2 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
US20080132543A1 (en) * 2004-10-26 2008-06-05 Wha Bin Im Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
AU2005304764B2 (en) * 2004-11-08 2012-07-12 Allergan, Inc. Substituted pyrrolidone compounds as EP4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
WO2006080323A1 (ja) * 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ６員環化合物及びその用途
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US8420628B2 (en) * 2005-05-06 2013-04-16 Allergan, Inc. Substituted beta-lactams
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
WO2008076703A1 (en) 2006-12-18 2008-06-26 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
EP2147672A4 (en) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
ES2395875T3 (es) * 2007-05-23 2013-02-15 Allergan, Inc. Lactamas cíclicas para el tratamiento del glaucoma o de la presión intraocular elevada
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
EP2488168A1 (en) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Combination therapy treatment for viral infections
TWI555744B (zh) * 2010-03-08 2016-11-01 Kaken Pharma Co Ltd Novel EP4 agonists
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012112757A2 (en) 2011-02-17 2012-08-23 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814527A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2014015246A1 (en) 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
SG11201507470WA (en) 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP6368351B2 (ja) 2013-03-15 2018-08-01 ケイマン ケミカル カンパニー， インコーポレーテッド ジフルオロラクタムアナログを合成する方法
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
WO2015009991A2 (en) * 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN106458859B (zh) 2014-06-06 2019-08-30 阿勒根公司 作为治疗性化合物的新型ep4激动剂
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
EP3307747A4 (en) 2015-06-12 2019-02-27 Simon Fraser University AMIDE-LINKED EP4-BISPHOSPHONATE AGONIST COMPOUNDS AND USES THEREOF
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
KR102446027B1 (ko) 2017-12-25 2022-09-21 아사히 가세이 파마 가부시키가이샤 함질소 6원환 화합물
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (da) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
IL113112A (en) 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
CA2346038A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
OA12117A (en) * 1999-12-22 2006-05-04 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
ES2263557T3 (es) * 2000-01-31 2006-12-16 Pfizer Products Inc. Uso de agonistas selectivos del receptor 4(ep4) de prostablandinas (pge2) para el tratamiento de insuficiencia renal aguda y cronica.
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
MXPA03004623A (es) * 2000-11-27 2003-09-05 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
EE200300246A (et) 2003-10-15
MA26961A1 (fr) 2004-12-20
ECSP034623A (es) 2003-07-25
NZ525164A (en) 2005-04-29
JP2004521869A (ja) 2004-07-22
TNSN01166A1 (fr) 2005-11-10
NO20032360D0 (no) 2003-05-26
WO2002042268A2 (en) 2002-05-30
US6747054B2 (en) 2004-06-08
BG107697A (en) 2004-01-30
TW200424170A (en) 2004-11-16
PA8533901A1 (es) 2002-11-28
GT200100238A (es) 2002-06-26
EP1339678A2 (en) 2003-09-03
DE60130675D1 (de) 2007-11-08
IL155368A0 (en) 2003-11-23
US7192979B2 (en) 2007-03-20
EA200300379A1 (ru) 2003-08-28
JP3984164B2 (ja) 2007-10-03
HUP0400807A2 (hu) 2004-07-28
MXPA03004623A (es) 2003-09-05
CN1476429A (zh) 2004-02-18
AU2002210848A1 (en) 2002-06-03
CZ20031257A3 (cs) 2004-04-14
US20030149086A1 (en) 2003-08-07
KR20030053063A (ko) 2003-06-27
BR0115687A (pt) 2003-09-09
CA2429850A1 (en) 2002-05-30
SV2003000746A (es) 2003-01-13
US20040259921A1 (en) 2004-12-23
PL362030A1 (en) 2004-10-18
ATE374182T1 (de) 2007-10-15
ES2291361T3 (es) 2008-03-01
IS6775A (is) 2003-04-10
EP1339678B1 (en) 2007-09-26
DE60130675T2 (de) 2008-01-24
SI1339678T1 (sl) 2007-12-31
GT200100238AA (es) 2004-05-12
CY1106976T1 (el) 2012-09-26
WO2002042268A3 (en) 2002-07-25
CA2429850C (en) 2008-12-30
NO20032360L (no) 2003-07-23
OA12533A (en) 2006-06-05
US6552067B2 (en) 2003-04-22
PT1339678E (pt) 2007-11-30
ZA200302803B (en) 2004-04-13
JP2007197467A (ja) 2007-08-09
PE20020637A1 (es) 2002-07-18
US20020065308A1 (en) 2002-05-30
AR035074A1 (es) 2004-04-14
SK5562003A3 (en) 2004-08-03
HN2001000266A (es) 2002-01-30
UY27038A1 (es) 2002-07-31

Similar Documents

Publication Publication Date Title
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
CY2017020I2 (el) Στεροειδη ως αγωνιστες για τους υποδοχεις fxr
IS6785A (is) EP4 viðtakahindrar til meðhöndlunar á liðagigt
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
NO20023672L (no) Sammensetninger for kontrollert frigivelse
DK1553929T3 (da) Sammensætning med kontrolleret frigivelse.
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1142477T3 (da) Sammensætninger med reguleret frigivelse
DK1201655T3 (da) Fremgangsmåde til fremstilling af non-steroide glucocorticoidreceptormodulatorer
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1225878T3 (da) RAR-gamma-selektive retinoidagonister til behandling af emfysem
ITMI20001699A0 (it) Agente coesivizzante inorganico per impasti cementizi autocompattanti
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1309607T3 (da) Fremgangsmåde til fremstilling af LHRH-antagonister
DK1281707T3 (da) Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
ITMO20030065A0 (it) Dispositivo per l'ancoraggio di lastre ceramiche.
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
ES1049390Y (es) Dispositivo de anclaje para encofrados de hormigon.
DK1099490T3 (da) Indretning til afkapning af rør
ID30106A (id) Pelarutan enzimatik modulator-modulator reseptor estrogen selektif
ES1049092Y (es) Dispositivo de alineacion para encofrados de hormigon.